Skip to content

Castle Biosciences CSTL Other Working Capital

Other Working Capital at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$11.4M+40.7%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$21K-106%
NeoGenomics logo
NeoGenomicsNEO
$402K-47.9%
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
-$1K+95.2%
GeneDx Holdings logo
GeneDx HoldingsWGS
$1.03M+36.6%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$98K+1,533%

Other financials

Income statement

See full
Revenue$83.7M-4.9%
Gross profit$63.1M-11.8%
Operating income-$18.4M+34.1%
Net income-$14.5M+43.8%
EPS (diluted)-$0.49+45.6%

Balance sheet

See full
Cash & equivalents$63.8M-28.9%
Total debt$36.7M+42.1%
Total equity$461.4M+4.8%
Total assets$547.8M+9.2%

Cash flow

See full
Operating cash flow-$22.1M-267%
CapEx$12.5M+163%
Free cash flow-$34.6M-221%

Valuation

See full
Market cap$694.86M+29.9%
Enterprise value$667.82M+41.8%
P/S+0.5×

Profitability

See full
Gross margin77.9%-4.1pp
Operating margin-9.8%-30.8pp
Net margin-3.8%-10.2pp
FCF margin1.3%-10.7pp

Returns & leverage

See full
Return on equity-2.8%-10.6pp
Debt / equity0.1×0.0×
Current ratio6.7×-2.6×

Where this comes from

Reported directly by Castle Biosciences in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Castle Biosciences's other working capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Castle Biosciences's other working capital?
Castle Biosciences (CSTL) reported other working capital of -$532K in Q1 2026.
How has Castle Biosciences's other working capital changed year-over-year?
Castle Biosciences's other working capital decreased by 1673.3% year-over-year, from -$30K to -$532K.
What does other working capital mean?
Net change in working capital items not separately classified — a residual balancing item.